Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) EBIT Margin (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of EBIT Margin data on record, last reported at 526.49% in Q4 2025.

  • For Q4 2025, EBIT Margin fell 23043.0% year-over-year to 526.49%; the TTM value through Dec 2025 reached 519.75%, down 25018.0%, while the annual FY2025 figure was 519.75%, 25018.0% down from the prior year.
  • EBIT Margin reached 526.49% in Q4 2025 per OCUL's latest filing, down from 472.35% in the prior quarter.
  • Across five years, EBIT Margin topped out at 127.41% in Q3 2023 and bottomed at 597.47% in Q1 2025.
  • Average EBIT Margin over 5 years is 255.49%, with a median of 176.34% recorded in 2021.
  • Peak YoY movement for EBIT Margin: surged 96721bps in 2021, then crashed -38346bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 146.64% in 2021, then grew by 6bps to 137.56% in 2022, then rose by 2bps to 135.46% in 2023, then tumbled by -119bps to 296.06% in 2024, then tumbled by -78bps to 526.49% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 526.49% in Q4 2025, 472.35% in Q3 2025, and 502.58% in Q2 2025.